Media

Deal creates new sales channel and revenue opportunities for OxC-betaTM Livestock with commercial farms and large integrated feed producers Ottawa, ON / Business Wire / February 18, 2020 / – Avivagen Inc.  (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune …Read More

Ottawa, ON / Business Wire / January 29, 2020 / – Avivagen Inc. (TSXV:VIV, OTCQB: VIVXF) (“Avivagen”) announces its CEO update to shareholders. To our Shareholders: The past twelve months have been a period of exceptional accomplishment and achievement for Avivagen. As a Company, we have taken tremendous strides in the development and commercialization of …Read More

Ottawa, ON /Business Wire/ January 27, 2020 / — Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to announce the successful second and final closing of its previously announced non-brokered private placement (the “Offering”).   …Read More

TORONTO, Jan. 23, 2020 /CNW/ – Mimi’s Rock Corp. (TSXV:MIMI) and Avivagen Inc. (TSXV:VIV) (collectively “the Companies”) are pleased to announce the Dr Tobias Dog Chews containing the proprietary Avivagen OxC-BetaTM additive are now available in the United States on Amazon and Drtobias.com. “We’ve been working closely with the Avivagen team to launch the first Dr Tobias branded product into …Read More

Ottawa, ON /Business Wire/ January 20, 2020 / — Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to provide an update on the status of its previously announced non-brokered private placement (the “Offering”) of …Read More